We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+1.91%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.7B
AUM Growth
+$101M
Cap. Flow
+$158M
Cap. Flow %
1.07%
Top 10 Hldgs %
22.11%
Holding
946
New
64
Increased
332
Reduced
304
Closed
69

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$57.5M
2
AZN icon
AstraZeneca
AZN
+$44.9M
3
ADSK icon
Autodesk
ADSK
+$43.5M
4
MELI icon
Mercado Libre
MELI
+$40.7M
5
AMGN icon
Amgen
AMGN
+$33.6M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$92.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$88M
3
BABA icon
Alibaba
BABA
+$73.8M
4
MRK icon
Merck
MRK
+$49.8M
5
MXIM
Maxim Integrated Products
MXIM
+$48.5M

Sector Composition

Rank Sector Weight
1 Healthcare 32.09%
2 Technology 24.53%
3 Financials 9.08%
4 Communication Services 8.24%
5 Consumer Discretionary 7.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FIVN icon
226
FIVE9
FIVN
$2.1B
$13.7M 0.09%
+86,075
New +$15.7M
TRI icon
227
Thomson Reuters
TRI
$46.8B
$13.7M 0.09%
117,434
+47,008
+67% +$5.48M
NTLA icon
228
Intellia Therapeutics
NTLA
$1.48B
$13.6M 0.09%
101,127
– –
RVMD icon
229
Revolution Medicines
RVMD
$38.3B
$13.5M 0.09%
489,382
+95,312
+24% +$2.77M
UNP icon
230
Union Pacific
UNP
$174B
$13.2M 0.09%
64,402
-4,328
-6% -$935K
EW icon
231
Edwards Lifesciences
EW
$48.7B
$13M 0.09%
114,949
+2,071
+2% +$236K
LPX icon
232
Louisiana-Pacific
LPX
$5.21B
$12.9M 0.09%
210,842
+82,094
+64% +$4.84M
MGNX icon
233
MacroGenics
MGNX
$235M
$12.7M 0.09%
608,523
– –
ECL icon
234
Ecolab
ECL
$78.9B
$12.7M 0.09%
60,961
-5,548
-8% -$1.22M
AXP icon
235
American Express
AXP
$225B
$12.6M 0.09%
75,238
+22,509
+43% +$3.76M
NEO icon
236
NeoGenomics
NEO
$2.04B
$12.5M 0.09%
260,120
+72,788
+39% +$3.37M
SPWH icon
237
Sportsman's Warehouse
SPWH
$45.3M
$12.5M 0.08%
709,064
– –
T icon
238
AT&T
T
$168B
$12.4M 0.08%
609,163
-31,617
-5% -$664K
CVA
239
DELISTED
Covanta Holding Corporation
CVA
$12.4M 0.08%
+615,930
New +$12.2M
ARWR icon
240
Arrowhead Research
ARWR
$12.1B
$12.3M 0.08%
196,408
– –
MAS icon
241
Masco
MAS
$14.5B
$12.2M 0.08%
220,195
-68,659
-24% -$4.07M
BCAB icon
242
BioAtla
BCAB
$5.61M
$11.9M 0.08%
8,093
+5,501
+212% +$10.7M
NGM
243
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$11.9M 0.08%
564,059
– –
AVTR icon
244
Avantor
AVTR
$9.51B
$11.8M 0.08%
288,432
-64,230
-18% -$2.51M
TGTX icon
245
TG Therapeutics
TGTX
$8.29B
$11.8M 0.08%
353,983
– –
UMPQ
246
DELISTED
Umpqua Holdings Corp
UMPQ
$11.8M 0.08%
581,439
+194,023
+50% +$3.72M
ZBRA icon
247
Zebra Technologies
ZBRA
$13.5B
$11.6M 0.08%
22,528
+9,475
+73% +$5.28M
CHNG
248
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$11.6M 0.08%
553,958
– –
KDNY
249
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.5M 0.08%
902,537
+27,413
+3% +$361K
PCRX icon
250
Pacira BioSciences
PCRX
$1.04B
$11.5M 0.08%
+204,960
New +$11.8M
8 9
10
11 12

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q3 2021 Portfolio in Review

As of Q3 2021, Candriam SCA held 946 positions worth $14.7B, up 0.69% from $14.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA's Q3 2021 filing shows 64 new, 332 increased, 304 reduced and 69 closed positions. Its largest new stake was FIVE9: 86,075 shares worth $13.7M. The largest sale was Alexion Pharmaceuticals, an estimated $92.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q3 2021 buy was FIVE9: 86,075 shares worth $13.7M.
  • Candriam SCA added most to Johnson & Johnson in Q3 2021, an estimated $57.5M increase.
  • Candriam SCA's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $88M.
  • Candriam SCA fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $92.5M.
  • Candriam SCA's ten largest holdings make up 22% of its $14.7B portfolio in Q3 2021.
  • Candriam SCA opened 64 new positions and closed 69 in Q3 2021.
  • Candriam SCA's portfolio value rose 0.69% quarter-over-quarter to $14.7B.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.